← The patent line

Chlorpheniramine Maleate; Ibuprofen; Pseudoephedrine Hydrochloride

Sold as ADVIL ALLERGY SINUS, CHILDREN'S ADVIL ALLERGY SINUS · given by oral

Within a year until it comes off patent
6 mo
Until anyone may copy it
Protection runs to 2027-02-28
6
Trials running now
59 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Haleon Us Holdings Llc
Approval holder
the only company permitted to sell it today
2027-02
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Hepatitis BHealthyCommon Cold
03

Who is paying for the research

Arrowhead Pharmaceuticals
Company
6
Hospital de Clinicas de Porto Aleg
University or hospital
3
Dr. Ferrer BioPharma
Company
3

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07626437Phase 32026 · 620 people · recruiting now
Fixed-dose Combination of 1000 mg Dipyrone M

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line